Additionally, the measurement of several serum biomarkers, including Krebs von den Lungen-6 antigen [40], CD4+CXCR4+ T cells [41], microRNA-200c [42], soluble CD206 [43], and progranulin [44], succeeded to predict short-term or long-term prognosis in patients with PM/DM-ILD. This evidence concerns the gene CD4 and dermatomyositis.